GSK ROE 2010-2022 | GSK
GSK ROE - Return on Equity Historical Data | |||
---|---|---|---|
Date | TTM Net Income | Shareholder's Equity | Return on Equity |
2022-12-31 | $18.50B | $12.49B | 90.74% |
2022-09-30 | $16.61B | $10.27B | 67.51% |
2022-06-30 | $6.07B | $28.43B | 20.56% |
2022-03-31 | $6.97B | $30.37B | 23.26% |
2021-12-31 | $6.03B | $29.35B | 20.36% |
2021-09-30 | $6.00B | $29.99B | 20.73% |
2021-06-30 | $6.00B | $30.16B | 21.33% |
2021-03-31 | $6.86B | $28.97B | 25.56% |
2020-12-31 | $7.38B | $26.72B | 28.37% |
2020-09-30 | $8.12B | $26.64B | 32.21% |
2020-06-30 | $8.42B | $24.99B | 34.94% |
2020-03-31 | $6.86B | $25.74B | 36.43% |
2019-12-31 | $5.93B | $23.44B | 44.00% |
2019-09-30 | $5.56B | $22.27B | 62.85% |
2019-06-30 | $5.49B | $3.82B | 122.35% |
2019-03-31 | $4.85B | $4.39B | 106.35% |
2018-12-31 | $4.84B | $4.90B | 102.56% |
2018-09-30 | $2.83B | $4.85B | 61.39% |
2018-06-30 | $2.57B | $4.11B | 51.62% |
2018-03-31 | $1.74B | $5.00B | 32.45% |
2017-12-31 | $1.98B | $4.50B | 33.75% |
2017-09-30 | $2.97B | $6.32B | 46.38% |
2017-06-30 | $2.45B | $5.66B | 39.83% |
2017-03-31 | $2.05B | $6.93B | 32.87% |
2016-12-31 | $1.16B | $6.73B | 16.93% |
2016-09-30 | $0.30B | $5.25B | 3.50% |
2016-06-30 | $0.07B | $6.06B | 0.67% |
2016-03-31 | $0.93B | $9.37B | 6.91% |
2015-12-31 | $12.77B | $13.57B | 83.05% |
2015-09-30 | $14.87B | $14.47B | 106.07% |
2015-06-30 | $14.68B | $16.16B | 114.69% |
2015-03-31 | $15.57B | $17.30B | 133.77% |
2014-12-31 | $4.44B | $8.14B | 42.76% |
2014-09-30 | $6.81B | $9.61B | 59.68% |
2014-06-30 | $7.73B | $11.51B | 66.37% |
2014-03-31 | $8.22B | $12.30B | 71.10% |
2013-12-31 | $8.56B | $12.22B | 74.82% |
2013-09-30 | $6.01B | $10.54B | 54.31% |
2013-06-30 | $6.25B | $11.17B | 55.78% |
2013-03-31 | $6.62B | $11.84B | 57.63% |
2012-12-31 | $7.30B | $10.70B | 59.34% |
2012-09-30 | $7.90B | $11.10B | 60.00% |
2012-06-30 | $8.28B | $12.35B | 60.44% |
2012-03-31 | $8.10B | $15.04B | 56.01% |
2011-12-31 | $8.41B | $14.16B | 57.33% |
2011-09-30 | $5.32B | $13.27B | 35.72% |
2011-06-30 | $5.21B | $15.40B | 33.21% |
2011-03-31 | $2.98B | $15.83B | 19.36% |
2010-12-31 | $2.60B | $15.07B | 16.32% |
2010-09-30 | $6.44B | $16.45B | 40.10% |
2010-06-30 | $6.60B | $14.24B | 41.94% |
2010-03-31 | $9.29B | $17.84B | 61.25% |
2009-12-31 | $8.92B | $15.67B | 65.52% |
Sector | Industry | Market Cap | Revenue |
---|---|---|---|
Medical | Medical - Biomedical and Genetics | $75.923B | $36.279B |
GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom. |
Stock Name | Country | Market Cap | PE Ratio |
---|---|---|---|
Bristol Myers Squibb (BMY) | United States | $140.576B | 8.70 |
Bio-Rad Laboratories (BIO.B) | United States | $13.735B | 32.61 |
QIAGEN (QGEN) | Netherlands | $10.436B | 19.34 |
Ginkgo Bioworks Holdings (DNA) | United States | $2.549B | 0.00 |
Arcus Biosciences (RCUS) | United States | $1.194B | 0.00 |
Biohaven (BHVN) | United States | $0.913B | 0.00 |
Emergent Biosolutions (EBS) | United States | $0.394B | 0.00 |
ADC Therapeutics SA (ADCT) | Switzerland | $0.152B | 0.00 |
Enzo Biochem (ENZ) | United States | $0.106B | 0.00 |
SQZ Biotechnologies (SQZ) | United States | $0.024B | 0.00 |
Gelesis Holdings (GLS) | United States | $0.012B | 0.00 |